Cross-Linking

A new Die Ophthalmologie review explains ELZA-sub400 cross-linking, an individualised protocol that fits the UV dose to each cornea, making cross-linking possible in keratoconus corneas as thin as 214 µm.
ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.
The Second Global Consensus on Keratoconus and Ectatic Diseases was published today, and ELZA played a key role in its development.
Our latest review on corneal cross-linking (CXL), published in Progress in Retinal and Eye Research, explores its evolution, advanced protocols like ELZA-PACE, and clinical applications.
The article by Lu et al. reports an in vitro study, conducted to determine whether high-fluence PACK-CXL can be accelerated while still maintaining its antibacterial efficacy. The study found that high-fluence PACK-CXL did indeed decrease the bacterial concentration of several clinically significant bacterial strains, including S. aureus, P. aeruginosa, and S. epidermidis. These strains are commonly implicated in bacterial keratitis and contact lens-associated keratitis. Furthermore, the authors found that higher total fluence PACK-CXL protocols led to a corresponding increase in bacterial killing ratio (BKR).
Models include SL-120 and SL-220
Speaker: Prof. Farhad Hafezi. ELZA Institute.
Meeting: Annual Meeting of the Delhi Ophthalmological Society
Date: December 2020
Language: English

 
Summary Annual meeting of the Delhi Ophthalmological Society. For more information, see here: http://dosonline.org/